Pfizer has deserted construction of a hemophilia A gene treatment it authorized from Sangamo Therapeutics, a transfer that might imperil Sangamo’s long term.
It’s a unexpected turnabout for Pfizer, which had indicated it could deliver the experimental remedy to regulators, albeit now not one this is prone to have an important affect at the pharma large or sufferers. Every other gene treatment for the uncommon bleeding dysfunction was once authorized remaining 12 months however has mustered little hobby, in large part as a result of standard-of-care is already top and gene treatments aren’t but healing.
Sangamo’s management, despite the fact that, were relying at the remedy to lend a hand save the beleaguered biotech. In step with the deal Sangamo inked in 2017, Pfizer nonetheless owed the California-based biotech $220 million in milestones.
STAT+ Unique Tale
Have already got an account? Log in
This newsletter is unique to STAT+ subscribers
Release this text — plus day by day protection and research of the biotech sector — by means of subscribing to STAT+.
Have already got an account? Log in
Person plans
Crew plans
View All Plans
To learn the remainder of this tale subscribe to STAT+.
Subscribe
/cdn.vox-cdn.com/uploads/chorus_asset/file/25814030/2183984509.jpg "The United States executive introduced a ‘ancient’ nuclear power deal")
